These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 25196853)
1. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. Jäger R; Harutyunyan AS; Rumi E; Pietra D; Berg T; Olcaydu D; Houlston RS; Cazzola M; Kralovics R Am J Hematol; 2014 Dec; 89(12):1107-10. PubMed ID: 25196853 [TBL] [Abstract][Full Text] [Related]
2. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients. Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303 [TBL] [Abstract][Full Text] [Related]
3. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100. Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696 [TBL] [Abstract][Full Text] [Related]
4. TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients. Matsuguma M; Yujiri T; Yamamoto K; Kajimura Y; Tokunaga Y; Tanaka M; Tanaka Y; Nakamura Y; Tanizawa Y Int J Hematol; 2019 Dec; 110(6):690-698. PubMed ID: 31571131 [TBL] [Abstract][Full Text] [Related]
5. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Olcaydu D; Rumi E; Harutyunyan A; Passamonti F; Pietra D; Pascutto C; Berg T; Jäger R; Hammond E; Cazzola M; Kralovics R Haematologica; 2011 Mar; 96(3):367-74. PubMed ID: 21173100 [TBL] [Abstract][Full Text] [Related]
6. The Hong T; Luo M; Liu Q Genet Test Mol Biomarkers; 2020 Apr; 24(4):181-187. PubMed ID: 32202925 [No Abstract] [Full Text] [Related]
7. TERT rs2736100 genotypes are associated with differential risk of myeloproliferative neoplasms in Swedish and Chinese male patient populations. Dahlström J; Liu T; Yuan X; Saft L; Ghaderi M; Wei YB; Lavebratt C; Li P; Zheng C; Björkholm M; Xu D Ann Hematol; 2016 Oct; 95(11):1825-32. PubMed ID: 27561898 [TBL] [Abstract][Full Text] [Related]
8. Advances in understanding the pathogenesis of familial myeloproliferative neoplasms. Rumi E; Cazzola M Br J Haematol; 2017 Sep; 178(5):689-698. PubMed ID: 28444727 [TBL] [Abstract][Full Text] [Related]
10. Germline genetic factors in the pathogenesis of myeloproliferative neoplasms. Bellanné-Chantelot C; Rabadan Moraes G; Schmaltz-Panneau B; Marty C; Vainchenker W; Plo I Blood Rev; 2020 Jul; 42():100710. PubMed ID: 32532454 [TBL] [Abstract][Full Text] [Related]
11. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Kilpivaara O; Mukherjee S; Schram AM; Wadleigh M; Mullally A; Ebert BL; Bass A; Marubayashi S; Heguy A; Garcia-Manero G; Kantarjian H; Offit K; Stone RM; Gilliland DG; Klein RJ; Levine RL Nat Genet; 2009 Apr; 41(4):455-9. PubMed ID: 19287384 [TBL] [Abstract][Full Text] [Related]
12. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population. Ohyashiki JH; Yoneta M; Hisatomi H; Iwabuchi T; Umezu T; Ohyashiki K BMC Med Genet; 2012 Jan; 13():6. PubMed ID: 22251709 [TBL] [Abstract][Full Text] [Related]
13. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Tapper W; Jones AV; Kralovics R; Harutyunyan AS; Zoi K; Leung W; Godfrey AL; Guglielmelli P; Callaway A; Ward D; Aranaz P; White HE; Waghorn K; Lin F; Chase A; Baxter EJ; Maclean C; Nangalia J; Chen E; Evans P; Short M; Jack A; Wallis L; Oscier D; Duncombe AS; Schuh A; Mead AJ; Griffiths M; Ewing J; Gale RE; Schnittger S; Haferlach T; Stegelmann F; Döhner K; Grallert H; Strauch K; Tanaka T; Bandinelli S; Giannopoulos A; Pieri L; Mannarelli C; Gisslinger H; Barosi G; Cazzola M; Reiter A; Harrison C; Campbell P; Green AR; Vannucchi A; Cross NC Nat Commun; 2015 Apr; 6():6691. PubMed ID: 25849990 [TBL] [Abstract][Full Text] [Related]
14. The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients. Zhang X; Hu T; Wu Z; Kang Z; Liu W; Guan M Int J Hematol; 2012 Nov; 96(5):611-6. PubMed ID: 23054641 [TBL] [Abstract][Full Text] [Related]
15. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617 [TBL] [Abstract][Full Text] [Related]
16. A TET2 rs3733609 C/T genotype is associated with predisposition to the myeloproliferative neoplasms harboring JAK2(V617F) and confers a proliferative potential on erythroid lineages. Shen XH; Sun NN; Yin YF; Liu SF; Liu XL; Peng HL; Dai CW; Xu YX; Deng MY; Luo YY; Zheng WL; Zhang GS Oncotarget; 2016 Feb; 7(8):9550-60. PubMed ID: 26843622 [TBL] [Abstract][Full Text] [Related]
17. MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients. Trifa AP; Bănescu C; Bojan AS; Voina CM; Popa Ș; Vișan S; Ciubean AD; Tripon F; Dima D; Popov VM; Vesa ȘC; Andreescu M; Török-Vistai T; Mihăilă RG; Berbec N; Macarie I; Coliţă A; Iordache M; Cătană AC; Farcaș MF; Tomuleasa C; Vasile K; Truică C; Todincă A; Pop-Muntean L; Manolache R; Bumbea H; Vlădăreanu AM; Gaman M; Ciufu CM; Popp RA Am J Hematol; 2018 Jan; 93(1):100-106. PubMed ID: 29047144 [TBL] [Abstract][Full Text] [Related]
18. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Hinds DA; Barnholt KE; Mesa RA; Kiefer AK; Do CB; Eriksson N; Mountain JL; Francke U; Tung JY; Nguyen HM; Zhang H; Gojenola L; Zehnder JL; Gotlib J Blood; 2016 Aug; 128(8):1121-8. PubMed ID: 27365426 [TBL] [Abstract][Full Text] [Related]